Halder Pritam, Kant Shashi, Singh Archana, Kaur Ravneet
Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India.
Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
J Family Med Prim Care. 2024 Nov;13(11):5009-5013. doi: 10.4103/jfmpc.jfmpc_725_24. Epub 2024 Nov 18.
Intravenous iron sucrose (IVIS) is a rapidly acting, safe, and effective treatment for moderate anemia among pregnant women. The effectiveness of IVIS at 6 months post IVIS infusion was unknown. We, therefore, assessed the mean increase in hemoglobin concentration and body iron replenishment status at 6 months after the last dose of IVIS infusion.
The study was conducted in 28 villages served by two primary health centers in district Faridabad, Haryana. The participants (n = 129), when originally recruited in 2020, were all moderately anemic (hemoglobin level 7.0 to 9.9 g/dL) pregnant women in either the second or third trimester of pregnancy. Their iron deficiency was calculated by Ganzoni's formula with additional allowance of 500 mg of depot iron. The calculated deficit was rounded off to the nearest 100 mg. The dose of IVIS was 300 mg of iron diluted in 300 ml of normal saline administered intravenously every third day till the full calculated dose was administered. In this study, we collected the follow-up blood specimen 6 months after the last dose of IVIS and measured the hemoglobin concentration, C-Reactive protein (CRP), and serum ferritin level. Hemoglobin concentration was measured using an automated hematology analyzer (Sysmex XS-1000i). Serum ferritin and CRP were measured by enhanced chemiluminescence immunoassay and the enzymatic heterogeneous, sandwich immunoassay method, respectively (VITROS ECiQ, Ortho Clinical Diagnostics, New Jersey, USA).
The mean [standard deviation (SD)] duration of time elapsed since the administration of the last dose of IVIS infusion was 6.4 (0.9) months. The mean (SD) hemoglobin level at the time of original recruitment (baseline) was 8.7 ± 0.8 g/dL. The mean (SD) increase in the hemoglobin concentration at 6 months follow-up was 3.2 [95% confidence interval (CI): 3.0-3.4)] g/dL. The median [interquartile range (IQR)] serum ferritin level (ng/mL) at follow-up was 28.1 (12.7, 61.5). A total of 10.2% of the participants had a raised (>10 mg/L) CRP level. Adjusting for CRP level and based on serum ferritin level, the proportion of participants who were iron-deficient was 35.3%. The proportion of participants who had any degree of anemia was 70.5%.
Administration of IVIS infusion was effective in raising the mean hemoglobin concentration and in replenishing the body iron reserve at 6 months post infusion.
静脉注射蔗糖铁(IVIS)是治疗孕妇中度贫血的一种起效迅速、安全且有效的方法。IVIS输注后6个月的有效性尚不清楚。因此,我们评估了最后一剂IVIS输注后6个月时血红蛋白浓度的平均升高情况及体内铁补充状态。
该研究在哈里亚纳邦法里达巴德地区由两个初级卫生中心服务的28个村庄进行。参与者(n = 129)于2020年最初招募时,均为妊娠中期或晚期的中度贫血(血红蛋白水平7.0至9.9 g/dL)孕妇。她们的缺铁情况通过甘佐尼公式计算,并额外增加500 mg储存铁。计算出的缺额四舍五入到最接近的100 mg。IVIS的剂量为300 mg铁稀释于300 ml生理盐水中,每三天静脉注射一次,直至给予全部计算剂量。在本研究中,我们在最后一剂IVIS输注后6个月采集随访血标本,测量血红蛋白浓度、C反应蛋白(CRP)和血清铁蛋白水平。血红蛋白浓度使用自动血液分析仪(Sysmex XS - 1000i)测量。血清铁蛋白和CRP分别通过增强化学发光免疫分析法和酶促异质夹心免疫分析法测量(VITROS ECiQ,美国新泽西州奥瑟临床诊断公司)。
自最后一剂IVIS输注以来经过的平均[标准差(SD)]时间为6.4(0.9)个月。最初招募时(基线)的平均(SD)血红蛋白水平为8.7±0.8 g/dL。随访6个月时血红蛋白浓度的平均(SD)升高为3.2 [95%置信区间(CI):3.0 - 3.4] g/dL。随访时血清铁蛋白水平(ng/mL)的中位数[四分位间距(IQR)]为28.1(12.7,61.5)。共有10.2%的参与者CRP水平升高(>10 mg/L)。根据血清铁蛋白水平并校正CRP水平后,缺铁参与者的比例为35.3%。有任何程度贫血的参与者比例为70.5%。
IVIS输注在输注后6个月有效提高了平均血红蛋白浓度并补充了体内铁储备。